Nyrada, Inc. · ASX:NYR
Nyrada — Kalkine Invest Nest 2020 Small Cap Investor Conference
22 slides from Nyrada's conference presentation, Feb 27, 2020
Slide 1: Nyrada Inc. Corporate Presentation February 2020
27 February 2020 Sydney, Australia For personal use only Nyrada Inc. Corporate Presentation February 2020 Nyrada Inc. (ASX: NYR) is pleased to provide shareholders and the market the attached corporate presentation, “Kalkine Invest Nest Presentation February 2020”. This document will be used at the
Slide 2: Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use For personal use only words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “
Slide 3: Improving Lives, Offering Hope
(ASX : NYR) For personal use only Improving Lives, Offering Hope Developing New Therapies for Cardiovascular and Neurological Disorders James Bonnar Chief Executive Officer KALKINE Invest-Nest February 2020
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities
Slide 5: What is Nyrada?
What is Nyrada? For personal use only Newly Listed Initial Public Biotechnology Offering (IPO) Company 16 January 2020 $8.5 Million Australian Securities Exchange (ASX) NYR 3
Slide 6: Mission & Business Model
Mission & Business Model For personal use only Innovative Treatments Clinical Need Aim Market Potential Commercial focus Problem Discovery/early phase Diverse pipeline Cardiovascular Neurology 4
Slide 7: Cholesterol Problem
For personal use only Cholesterol Problem 5
Slide 8: Cholesterol Problem
Cholesterol Problem For personal use only 1 in 3 Deaths attributed to Cardiovascular Disease 6
Slide 9: Cholesterol Problem (US)
Cholesterol Problem (US) For personal use only Total of 62.6 million US Adults with elevated LDL-C 27.4 million with elevated LDL-C take a statin 19.4 million unable to achieve LDL-C target despite taking statin therapy 7
Slide 10: Current Treatment Options
Current Treatment Options For personal use only Low cost Effective, combined with statin Suboptimal efficacy Expensive Side effects Inconvenient Global sales statins approx. US$19 billion 8
Slide 11: New Treatment Option
New Treatment Option For personal use only ❑ Launch in March 2020 ❑ US$3,600 per year Developed for use with a statin Modest LDL-C reduction over statin alone 9
Slide 12: Nyrada Cholesterol-Lowering Solution
Nyrada Cholesterol-Lowering Solution For personal use only Blocks action of PCSK9 on cholesterol receptor Statins increase PCSK9 levels High PCSK9 = high LDL cholesterol Small molecule PCSK9 inhibitor 10
Slide 13: What is Unique?
What is Unique? For personal use only Single pill Aim treatment Problem Convenient Cost- for patient effective 11
Slide 14: Cholesterol Drug Market (Non-Statin)
Cholesterol Drug Market (Non-Statin) For personal use only Evolocumab Marketed Amgen PCSK9 inhibitor Monoclonal (Repatha) Alirocumab Marketed Sanofi/Regeneron PCSK9 inhibitor Monoclonal (Praluent) The Medicines Injectable Inclisiran Phase III Company / Novartis PCSK9 siRNA siRNA Evinacumab Phase III
Slide 15: Brain Injury Problem
Brain Injury Problem For personal use only Each year in the US: - 2.8 million people suffer a traumatic brain injury - 800,000 suffer a stroke One drug Neurology/physical class for stroke. rehabilitation only Suitable to less than existing therapies 15% of patients Minutes Hours Days Initial injury
Slide 16: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only ❑ Treatment to prevent secondary brain injury ❑ Inhibitor of Ca2+ induced excitotoxicity Intravenous or intranasal for 3-5 days post-injury ❑ Concussion & severe head trauma ❑ Stroke 14
Slide 17: Brain Injury Drug Market (US)
Brain Injury Drug Market (US) For personal use only Traumatic Brain Injury (Moderate to Severe) Hospital admissions per year 280k Patients who present within 12-hour window (>75%) 210k Stroke Emergency room visits per year 650k Patients who present within 12-hour window (>75%) 490k Annual US market
Slide 18: Program Status
Program Status For personal use only Proof-of-concept First-in-human Lead optimisation established studies (Phase I) well-advanced Cholesterol-lowering Neuroprotection program program clinic late-2021 clinic mid-2022 16
Slide 19: Board of Directors
Board of Directors For personal use only Nyrada operates under the direction of a board of international calibre Track record in founding and realising the value of biotech companies Mr John Dr Graham Christopher Mr Peter Mr Marcus Dr Rüdiger Moore Kelly Cox Marks Frampton Weseloh Non- Non- Non- Non
Slide 20: Scientific Advisory Board
Scientific Advisory Board For personal use only International team of experts with vast experience in drug development Prof Gary Prof Junichi Prof David Prof Gilles Jim Palmer Housley Nabekura Burke Lambert PhD MSc PhD PhD MD DSc AC PhD 18
Slide 21: For personal use only
For personal use only Large, under-served therapeutic areas Compelling proof of concept data Right team to execute
Slide 22: Discover More & Follow Us
Discover More & Follow Us For personal use only Nyrada benefits from an international team of experts with deep experience in drug development to advise its board and management Neuroprotection Animation Cholesterol-Lowering Animation Recent PCSK9i Publication @nyrada_inc www.nyrada.com @nyrada_inc
Nyrada — Kalkine Invest Nest 2020 Small Cap Investor Conference on 6ix